The Executive Group for the Solidarity trial has implemented a temporary pause of the trial of hydroxychloroquine as a treatment for COVID-19 while the safety data is reviewed by the Data Safety Monitoring Committee.
The Executive Group will review published data, the interim analysis from the Solidarity trial by the trial Data Safety Monitoirng Committee, and the findings from other ongoing trials that include hydroxychloroquine as one of their study arms.
The Executive Group is withholding its final opinion until the comprehensive review of the evidence is available for consideration. The aim is to have this review conducted by mid-June.
The Solidarity Trial is an international clinical trial to help find an effective treatment for COVID-19, launched by WHO and partners. It is hoped that one or more of the treatments under trial will result in improving clinical outcomes in COVID-19 patients and save lives
More than 100 countries have expressed an interest in participating in the Solidarity Trial.
To date, over 400 hospitals in 35 countries are actively recruiting patients and nearly 3,500 patients have been enrolled from 17 countries.
For the full version of the press conference of 25 May 2020: https://youtu.be/g3biL-YDyAk
More information on COVID-19: